Jaros Joanna, Lio Peter
J Drugs Dermatol. 2019 Mar 1;18(3):235-238.
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.
低剂量纳曲酮(LDN)已在多种疾病中作为免疫调节和抗炎疗法进行了成功研究,这些疾病包括克罗恩病、纤维肌痛、重度抑郁症、癌症、慢性区域疼痛综合征、夏科-马里-图斯病和多发性硬化症。1-5最近,已证明LDN在治疗系统性硬化症、黑利-黑利病、扁平苔藓和点滴状银屑病等皮肤病方面具有非标签用途。6-9在本文中,我们研究了LDN在皮肤病治疗中的现有证据,并讨论了其在特应性皮炎(AD)治疗中的潜在应用。《药物皮肤病学杂志》。2019年;18(3):235-238。